Takeda Launches New Subsidiary in Peru - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Takeda Launches New Subsidiary in Peru



Takeda Pharmaceuticals International GmbH has expanded its presence in Latin America with the addition of a wholly-owned subsidiary in Peru. Takeda Peru will be headquartered in Lima and will be responsible for the sales and marketing of Takeda's products in Peru.

Takeda has a direct presence in Brazil, Mexico, Argentina, Venezuela, Colombia, Ecuador and now Peru. According to IMS Market Prognosis, pharmaceutical sales in those countries totaled $60 billion in 2012 and are expected to grow at a compound annual rate of 12.5% between 2013 and 2017.

It is estimated that Peru’s GDP totaled $200 billion in 2012 while pharmaceutical sales amounted to $1.5 billion and are expected to continue to grow by 8% during 2013*.

Julio Cesar Acevedo Orrego has been appointed country manager for Peru. He joins the organization from Takeda Colombia, where he headed the Takeda Sales and Marketing organization following the acquisition of Farmacol Laboratories.

Source: Takeda Pharmaceuticals

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
24%
Attracting a skilled workforce
30%
Obtaining/maintaining adequate financing
15%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans

Click here